ReviewJournal of lipid research2013
Regulation of signal transduction by HDL.
Review in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.Lipids in health and disease · 2017Pooled it
- Impact of altered HDL2b/HDL3 ratio on the function of innate immune cells in sepsis.Lipids in health and disease · 2026Article
- Dysfunction of the ABCA1 and ABCG1 Transporters and Their Impact on HDL Metabolism.Antioxidants (Basel, Switzerland) · 2025Review
- Sphingosine-1-phosphate signalling activates E-Syt1 to facilitate HDL-derived cholesterol transport.Nature cell biology · 2025Article
- Association of cerebrospinal fluid NPY with peripheral ApoA: a moderation effect of BMI.Nutrition & metabolism · 2024Article
- In the Beginning, Lipoproteins Cross the Endothelial Barrier.Journal of atherosclerosis and thrombosis · 2024Review
- Designer high-density lipoprotein particles enhance endothelial barrier function and suppress inflammation.Science signaling · 2024Article
- Review
- Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies.Pharmaceuticals (Basel, Switzerland) · 2022Review
- HBV Infection-RelatedJournal of immunology research · 2022Article
- Extensive diet-induced atherosclerosis in scavenger receptor class B type 1-deficient mice is associated with substantial leukocytosis and elevated vascular cell adhesion molecule-1 expression in coronary artery endothelium.Frontiers in physiology · 2022Article
- HDL and Scavenger Receptor Class B Type I (SRBI).Advances in experimental medicine and biology · 2022Review
- Post-Stroke Administration of L-4F Promotes Neurovascular and White Matter Remodeling in Type-2 Diabetic Stroke Mice.Frontiers in neurology · 2022Article
- High-density lipoproteins, reverse cholesterol transport and atherogenesis.Nature reviews. Cardiology · 2021Review
- Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.Cardiovascular diabetology · 2021Article
- Novel Functions of Endothelial Scavenger Receptor Class B Type I.Current atherosclerosis reports · 2021Review
- Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis.Nature communications · 2020Article
- Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2019Review
- Deletion of OSBPL2 in auditory cells increases cholesterol biosynthesis and drives reactive oxygen species production by inhibiting AMPK activity.Cell death & disease · 2019Article
- Association of acute Babesia canis infection and serum lipid, lipoprotein, and apoprotein concentrations in dogs.Journal of veterinary internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High density lipoprotein (HDL) cholesterol has direct effects on numerous cell types that influence cardiovascular and metabolic health. These include endothelial cells, vascular smooth-muscle cells, leukocytes, platelets, adipocytes, skeletal muscle myocytes, and pancreatic β cells. The effects of HDL or apoA-I, its major apolipoprotein, occur through the modulation of intracellular calcium, oxygen-derived free-radical production, numerous kinases, and enzymes, including endothelial nitric-oxide synthase (eNOS). ApoA-I and HDL also influence gene expression, particularly genes encoding mediators of inflammation in vascular cells. In many paradigms, the change in intracellular signaling occurs as a result of cholesterol efflux, with the cholesterol acceptor methyl-β-cyclodextrin often invoking responses identical to HDL or apoA-I. The ABC transporters ABCA1 and ABCG1 and scavenger receptor class B, type I (SR-BI) frequently participate in the cellular responses. Structure-function relationships are emerging for signal initiation by ABCA1 and SR-BI, with plasma membrane cholesterol binding by the C-terminal transmembrane domain of SR-BI uniquely enabling it to serve as a sensor of changes in membrane cholesterol. Further investigation of the processes underlying HDL and apoA-I modulation of intracellular signaling will potentially reveal new prophylactic and therapeutic strategies to optimize both cardiovascular and metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.